SIRIO(300791)2024-04-21 08:04Financial Performance - The company reported a revenue increase of 15% year-over-year, reaching approximately 1.2 billion yuan in 2023[12]. - The company has set a revenue guidance of 1.5 billion yuan for 2024, representing a projected growth of 25%[12]. - The company reported a revenue of 1.2 billion RMB for the fiscal year 2023, representing a 15% increase compared to the previous year[28]. - The company expects a revenue growth of 20% for the next fiscal year, projecting revenues to reach 1.44 billion RMB[28]. - The company's operating revenue for 2023 reached ¥3,582,022,297.17, representing a 42.87% increase compared to ¥2,507,261,818.80 in 2022[33]. - The net profit attributable to shareholders for 2023 was ¥281,038,527.77, a 32.39% increase from ¥212,285,578.09 in 2022[33]. - The total revenue for 2023 reached ¥3,582,022,297.17, representing a year-on-year increase of 42.87% compared to ¥2,507,261,818.80 in 2022[107]. - The main business revenue amounted to ¥3,568,107,343.10, accounting for 99.61% of total revenue, with a growth of 43.12% year-on-year[107]. User Growth and Market Expansion - User data indicates a growth in active customers by 25%, totaling 3 million users by the end of 2023[12]. - User data showed a growth in active users by 25%, reaching 5 million by the end of 2023[28]. - The company aims to expand its market reach in Europe and North America, targeting a 30% increase in international sales by 2025[12]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by 2025[28]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by the end of 2024[184]. Research and Development - The company has invested 100 million yuan in R&D for new product development, focusing on innovative health supplements[12]. - Research and development expenses increased by 18%, totaling 150 million RMB, focusing on innovative health solutions[28]. - The company has been actively involved in research and development of new health products to meet the growing demand in the nutrition and health food market[42]. - The company has established a product development team led by PhDs to continuously innovate in formula and dosage form technology[67]. - The company has developed innovative dosage forms such as gel soft capsules and probiotic crystal balls, enhancing product nutritional value through technological breakthroughs[69]. - The company launched several new health food products, including "Tian Can® DHA Algal Oil Soft Capsules" and "An Yi Jia® Cod Liver Oil Soft Capsules," with registration valid until 2028[92][93]. Acquisitions and Strategic Partnerships - The acquisition of Best Formulations in the US is expected to enhance the company's market presence and operational efficiency[12]. - The company completed a strategic acquisition of a competitor for 200 million RMB, enhancing its product portfolio[28]. - The company has acquired Best Formulations in the U.S. and established a cross-border factory in Zhuhai, strengthening global supply capabilities[69]. - The acquisition of 71.41% equity in Best Formulations LLC is aimed at expanding the company's business in the Americas and enhancing global market competitiveness[154]. Financial Management and Investments - The company plans to distribute a cash dividend of 11 yuan per 10 shares, alongside a capital increase of 3 shares for every 10 shares held[12]. - The company has a liquidity fund of 13,851 million CNY, which is fully utilized[146]. - The company invested ¥1,184,579,912.56 during the reporting period, a significant increase of 303.34% compared to the previous year[136]. - The company has committed to several investment projects, including a production base in Anshan with an investment of 69,585 million CNY, which is 84.11% completed[146]. Product Development and Innovation - New product launches contributed to 30% of total revenue, with three major products introduced in Q4 2023[28]. - The company focuses on six key categories: anti-aging, probiotics, beauty health, cardiovascular metabolism, immune enhancement, and sports nutrition, with strategies showing initial success in 2023[66]. - The company is focusing on building a flexible manufacturing system and an excellent supply chain to reduce costs and improve efficiency[103]. - The company is focusing on innovative product development, including plant-based soft capsules and probiotic products, to meet diverse health needs across different age groups[82]. Market Trends and Consumer Behavior - The global retail scale of the nutrition and health food market exceeded 223 billion by 2026[46]. - The U.S. nutrition and health food market grew to over 9.6 billion in 2023, with a year-on-year growth of over 5%[58]. Governance and Compliance - The company maintains a governance structure consisting of the shareholders' meeting, board of directors, supervisory board, and senior management, ensuring coordination and checks and balances among decision-making, supervision, and management[189]. - The board of directors comprises 7 members, including 3 independent directors, meeting legal and regulatory requirements[192]. - The company respects and protects the legitimate rights and interests of stakeholders, promoting balanced interests among shareholders, employees, and society[195]. - The company strictly adheres to legal regulations and its own disclosure management system, ensuring timely and fair information disclosure[198].